Study on Pharmacokinetic Interactions Between HS-10234 and Emtricitabine in Healthy Subjects: An Open-Label, Two-Sequence, Self-Controlled Phase I Trial

INTRODUCTION: HS-10234, a novel prodrug of tenofovir (TFV), functions by inhibiting nucleotide reverse transcriptase against retroviral infections including hepatitis B virus and human immunodeficiency virus (HIV). As it is a possible substitute for TFV co-administration with emtricitabine, determin...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Yeping, Chen, Wenjing, Yang, Guoping, Zou, Chan, Huang, Jie, Kuang, Yun, Shen, Kai, Zhang, Basheng, Yang, Shuang, Xiang, Hong, Li, Zhuo, Pei, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847640/
https://www.ncbi.nlm.nih.gov/pubmed/34727366
http://dx.doi.org/10.1007/s40121-021-00555-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847640/
https://www.ncbi.nlm.nih.gov/pubmed/34727366
http://dx.doi.org/10.1007/s40121-021-00555-y

Ejemplares similares